Tag

Financial Results

All articles tagged with #financial results

On Holding Boosts Outlook Amid Strong Q3 and Holiday Sales

Originally Published 2 months ago — by ONON

On reported a record-breaking third quarter in 2025 with a 24.9% increase in net sales to CHF 794.4 million, driven by strong demand across channels and regions, especially in apparel and Asia-Pacific. The company achieved a gross profit margin of 65.7% and an adjusted EBITDA margin of 22.6%, raising its full-year guidance with expected net sales of CHF 2.98 billion and continued profitability growth. Strategic investments, athlete achievements, and collaborations bolster its global premium brand position.

Lucid Reports Narrowed Q3 Losses Amid Production Challenges and Revenue Growth

Originally Published 2 months ago — by Lucid Motors

Lucid Motors reported strong Q3 2025 financial results with a 68% increase in revenue to $336.6 million, vehicle production up 116%, and a strategic partnership with NVIDIA to develop Level 4 autonomous driving technology. The company also increased its liquidity to approximately $5.5 billion following a credit facility expansion, and made organizational changes to accelerate growth and global expansion.

Uber Stock Declines Despite Strong Q3 Earnings and Rising Rides

Originally Published 2 months ago — by Investor's Business Daily

Featured image for Uber Stock Declines Despite Strong Q3 Earnings and Rising Rides
Source: Investor's Business Daily

Uber reported strong Q3 earnings with revenue and trip volume surpassing expectations, but its stock fell nearly 5% in premarket trading, possibly due to market reactions to its earnings report and guidance, despite the company's significant growth and positive outlook.

Merck Reports Strong Q3 Results Amid Mixed Outlook

Originally Published 2 months ago — by Merck.com

Featured image for Merck Reports Strong Q3 Results Amid Mixed Outlook
Source: Merck.com

Merck & Co. reported a 4% increase in worldwide sales to $17.3 billion in Q3 2025, driven by strong growth in KEYTRUDA and WINREVAIR, despite declines in GARDASIL sales. The company achieved significant pipeline milestones, including FDA approvals and positive trial results, and raised its full-year sales and EPS outlooks, reflecting ongoing strategic investments and acquisitions. Overall, Merck demonstrated robust financial performance and pipeline progress, positioning itself for continued growth in 2025.